Repurposing of atorvastatin emulsomes as a topical antifungal agent.
Atorvastatin
emulsomes
fungal infection
repurposing
topical
Journal
Drug delivery
ISSN: 1521-0464
Titre abrégé: Drug Deliv
Pays: England
ID NLM: 9417471
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
entrez:
26
11
2022
pubmed:
27
11
2022
medline:
30
11
2022
Statut:
ppublish
Résumé
Cutaneous fungal infection therapy confronts several issues concerning skin permeation in addition to drug resistance and adverse effects of conventional drugs. The repurposing strategy is supposed to overcome some of those therapeutic obstacles. Recently, atorvastatin (ATO) revealed antifungal activity. ATO is an antihyperlipidemic drug with pH-dependent solubility, which limits skin permeation. This study aims to improve ATO antifungal activity by encapsulation in an emulsomes (EMLs) system, which seeks to ameliorate skin penetration. Therefore, multiple factors were investigated according to the One-Factor-at-a-Time (OFAT) design to achieve the optimum formula with targeted characteristics. Minimizing particle-size and polydispersity-index, besides elevating zeta-potential (ZP) and entrapment-efficiency were the desirable responses during assessing 11 factors. The selected ATO-EMLs formula (E21) recorded 250.5 nm in particle size, polydispersity index of 0.4, ZP of -25.93 mV, and 83.12% of drug entrapped. Morphological study of E21 revealed spherical core-shell vesicles in nanosize. DSC, XRD, and FTIR were conducted to discover the physicochemical properties and confirm emulsomes formation. Optimized ATO-EMLs slowed drug release rate as only 75% of ATO was released after 72 h. Stability study recommended storage between 2 and 8 °C. The
Identifiants
pubmed: 36428290
doi: 10.1080/10717544.2022.2149898
pmc: PMC9707382
doi:
Substances chimiques
Antifungal Agents
0
Atorvastatin
A0JWA85V8F
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3414-3431Références
Arch Pharm Res. 2015 Dec;38(12):2193-200
pubmed: 26152876
Pharmaceutics. 2018 May 18;10(2):
pubmed: 29783687
AAPS PharmSciTech. 2020 Sep 25;21(7):263
pubmed: 32978691
Eur J Pharm Biopharm. 2004 Sep;58(2):301-16
pubmed: 15296957
Int J Pharm. 2009 Oct 1;380(1-2):181-8
pubmed: 19576973
Front Bioeng Biotechnol. 2020 Feb 11;8:50
pubmed: 32117930
Int J Biol Macromol. 2016 Nov;92:254-269
pubmed: 27397719
Int J Nanomedicine. 2021 Jan 08;16:119-132
pubmed: 33447031
J Liposome Res. 2019 Sep;29(3):283-290
pubmed: 30501429
Antibiotics (Basel). 2020 Nov 15;9(11):
pubmed: 33203147
Pharmaceutics. 2021 May 24;13(6):
pubmed: 34073780
J Microencapsul. 2013;30(3):225-36
pubmed: 23088318
Curr Pharm Biotechnol. 2015;16(4):392-405
pubmed: 25697368
J Young Pharm. 2011 Jul;3(3):197-204
pubmed: 21897658
Antioxidants (Basel). 2020 May 13;9(5):
pubmed: 32414040
Eur J Clin Microbiol Infect Dis. 2018 Jun;37(6):1125-1135
pubmed: 29569046
PLoS One. 2014 Dec 12;9(12):e113558
pubmed: 25502102
Ultrason Sonochem. 2010 Mar;17(3):628-32
pubmed: 19914854
AAPS J. 2010 Sep;12(3):263-71
pubmed: 20373062
Int J Pharm. 2021 May 15;601:120483
pubmed: 33737098
Eur J Pharm Sci. 2001 May;13(2):123-33
pubmed: 11297896
Pharmaceutics. 2022 Feb 14;14(2):
pubmed: 35214142
J Nutr Sci Vitaminol (Tokyo). 2009 Jun;55(3):271-8
pubmed: 19602836
Expert Opin Drug Deliv. 2009 Aug;6(8):813-25
pubmed: 19569979
Pharmacol Ther. 2020 Apr;208:107483
pubmed: 31953128
Pharmacol Res. 2014 Oct;88:3-11
pubmed: 24657242
Nat Rev Drug Discov. 2019 Jan;18(1):41-58
pubmed: 30310233
J Pharm Pharmacol. 2006 Mar;58(3):321-6
pubmed: 16536898
Acta Pharm. 2014 Jun;64(2):139-56
pubmed: 24914716
World J Microbiol Biotechnol. 2021 Oct 11;37(11):191
pubmed: 34632522
Int J Pharm. 2016 Apr 30;503(1-2):127-40
pubmed: 26924357
J Exp Clin Cancer Res. 2021 Jul 24;40(1):241
pubmed: 34303383
AAPS PharmSciTech. 2022 Mar 9;23(3):81
pubmed: 35266075
Open Forum Infect Dis. 2022 Jan 10;9(1):ofab593
pubmed: 35036461
Pharmaceuticals (Basel). 2021 May 20;14(5):
pubmed: 34065420
Br J Pharmacol. 2011 Mar;162(6):1239-49
pubmed: 21091654
Pharmaceutics. 2021 Oct 19;13(10):
pubmed: 34684020
J Control Release. 2017 May 28;254:10-22
pubmed: 28344015
J Microencapsul. 2015;32(2):157-65
pubmed: 25329530
Front Microbiol. 2018 Jul 03;9:1351
pubmed: 30018595
Drug Deliv. 2016 Oct;23(8):3101-3110
pubmed: 27854145
Pharmaceutics. 2020 Oct 11;12(10):
pubmed: 33050567
Expert Opin Drug Deliv. 2014 Dec;11(12):1865-83
pubmed: 25152197
Pharmaceutics. 2021 Jan 28;13(2):
pubmed: 33525642
Int J Pharm. 2017 Jan 30;517(1-2):256-268
pubmed: 27956194
Int J Nanomedicine. 2014 Nov 26;9:5449-60
pubmed: 25473283
Med Pharm Rep. 2019 Oct;92(4):368-373
pubmed: 31750437
Acta Pharm Sin B. 2015 Jan;5(1):79-88
pubmed: 26579429
Drug Des Devel Ther. 2020 Aug 12;14:3271-3289
pubmed: 32848366
Int J Pharm. 2017 Jul 15;527(1-2):1-11
pubmed: 28522423
Front Microbiol. 2019 Jan 28;10:41
pubmed: 30745898